Option chain shows key data for TransMedics Gr's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for TransMedics Gr.

TransMedics Gr (NASDAQ:TMDX) Stock, Option Chain

TransMedics Gr

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

TransMedics Group

Porto,,Portugal,-,October,29,,2024,-,Silhouette,Of,Hand

News

Health Care

Movers

Trading Ideas

General

GKOS

ISRG

TMDX

TransMedics faces allegations from Scorpion Capital of fraud and organ trafficking, while the company rebuffs the claims as baseless market manipulation.

Short Seller Accuses TransMedics Of &#39;Mafia Style&#39; Scheme, Organ Transplant Company Says Short Seller Manipulating Market

Equities

Mid Cap

Guidance

Management

TransMedics Group appoints new CFO, Gerardo Hernandez, and adjusts financial outlook for 2024.

TransMedics Ushers In New CFO, Tightens 2024 Revenue Goals

zscaler shutter2

Pre-Market Outlook

Markets

AFYA

CLSK

FRME

GRDN

INDI

Zscaler, TransMedics Group And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

TransMedics Group Inc

Embraer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERJ#NYSE">ERJ</a>), one of the global leaders in the aerospace industry, delivered 75 aircraft in 4Q24 – or 27% higher than in the previous quarter (3Q24), when 59 aircraft were delivered, and equal to the volume of the same period of 2023 (4Q23). For the full year, 206 aircraft were delivered in 2024 – a number 14% higher than the 181 recorded in 2023.
With 31 deliveries in the last three months of the year, Commercial Aviation reached 73 new aircraft in 2024 (at the top of the revised 70-73 guidance range for the year, and inside the original 72-80 guidance). Meanwhile, Executive Aviation was responsible for another 44 jets in the quarter, and for the total of 130 deliveries in the year (at the midpoint of the original guidance). In comparison with 2023, growth in these business units was +14% and +13%, respectively. Last, but not least, Defense &amp; Security also surpassed the previous year's result with the delivery of 3 new C-390 Millennium in 2024 versus 2 in 2023.
 &nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Deliveries by Segment</td>
<td colspan="1" rowspan="1">4Q24</td>
<td colspan="1" rowspan="1">3Q24</td>
<td colspan="1" rowspan="1">4Q23</td>
<td colspan="1" rowspan="1">2024 FY</td>
<td colspan="1" rowspan="1">2023 FY</td>
<td colspan="1" rowspan="1">2024 Guidance</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Executive Aviation</td>
<td colspan="1" rowspan="1">44</td>
<td colspan="1" rowspan="1">41</td>
<td colspan="1" rowspan="1">49</td>
<td colspan="1" rowspan="1">130</td>
<td colspan="1" rowspan="1">115</td>
<td colspan="1" rowspan="1">125-135</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Phenom 100</td>
<td colspan="1" rowspan="1">3</td>
<td colspan="1" rowspan="1">4</td>
<td colspan="1" rowspan="1">6</td>
<td colspan="1" rowspan="1">10</td>
<td colspan="1" rowspan="1">11</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Phenom 300</td>
<td colspan="1" rowspan="1">19</td>
<td colspan="1" rowspan="1">18</td>
<td colspan="1" rowspan="1">24</td>
<td colspan="1" rowspan="1">65</td>
<td colspan="1" rowspan="1">63</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Light Jets</td>
<td colspan="1" rowspan="1">22</td>
<td colspan="1" rowspan="1">22</td>
<td colspan="1" rowspan="1">30</td>
<td colspan="1" rowspan="1">75</td>
<td colspan="1" rowspan="1">74</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Praetor 500</td>
<td colspan="1" rowspan="1">13</td>
<td colspan="1" rowspan="1">9</td>
<td colspan="1" rowspan="1">10</td>
<td colspan="1" rowspan="1">28</td>
<td colspan="1" rowspan="1">20</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Praetor 600</td>
<td colspan="1" rowspan="1">9</td>
<td colspan="1" rowspan="1">10</td>
<td colspan="1" rowspan="1">9</td>
<td colspan="1" rowspan="1">27</td>
<td colspan="1" rowspan="1">21</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Medium Jets</td>
<td colspan="1" rowspan="1">22</td>
<td colspan="1" rowspan="1">19</td>
<td colspan="1" rowspan="1">19</td>
<td colspan="1" rowspan="1">55</td>
<td colspan="1" rowspan="1">41</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Commercial Aviation</td>
<td colspan="1" rowspan="1">31</td>
<td colspan="1" rowspan="1">16</td>
<td colspan="1" rowspan="1">25</td>
<td colspan="1" rowspan="1">73</td>
<td colspan="1" rowspan="1">64</td>
<td colspan="1" rowspan="1">70-73</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">E195-E2</td>
<td colspan="1" rowspan="1">18</td>
<td colspan="1" rowspan="1">10</td>
<td colspan="1" rowspan="1">17</td>
<td colspan="1" rowspan="1">39</td>
<td colspan="1" rowspan="1">38</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">E190-E2</td>
<td colspan="1" rowspan="1">2</td>
<td colspan="1" rowspan="1">2</td>
<td colspan="1" rowspan="1">1</td>
<td colspan="1" rowspan="1">8</td>
<td colspan="1" rowspan="1">1</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">E175</td>
<td colspan="1" rowspan="1">11</td>
<td colspan="1" rowspan="1">4</td>
<td colspan="1" rowspan="1">7</td>
<td colspan="1" rowspan="1">26</td>
<td colspan="1" rowspan="1">25</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Total Commercial &amp; Executive</td>
<td colspan="1" rowspan="1">75</td>
<td colspan="1" rowspan="1">57</td>
<td colspan="1" rowspan="1">74</td>
<td colspan="1" rowspan="1">203</td>
<td colspan="1" rowspan="1">179</td>
<td colspan="1" rowspan="1">195-208&#x2A;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="4"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Defense &amp; Security</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">2</td>
<td colspan="1" rowspan="1">1</td>
<td colspan="1" rowspan="1">3</td>
<td colspan="1" rowspan="1">2</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">C-390 Millennium</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">2</td>
<td colspan="1" rowspan="1">1</td>
<td colspan="1" rowspan="1">3</td>
<td colspan="1" rowspan="1">2</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">A-29 Super Tucano&nbsp;</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="2" rowspan="1">&#x2A;Excludes C-390 Millennium and A-29 Super Tucano deliveries</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>

Embraer-Empresa Brasileira De Aeronautica

Embraer Reached 75 Deliveries In Q4, For A Total Of 206 New Aircraft In The Year

Legal

Trump Treasury Pick Bessent Says If U.S. Steel-Nippon Steel Merger Returns To CFIUS Review, Panel Will Conduct Same Review As It Always Does

TD Cowen analyst Joseph Giordano maintains Flowserve (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLS#NYSE">FLS</a>) with a Buy and raises the price target from $60 to $75.

Price Target

Analyst Ratings

TD Cowen Maintains Buy on Flowserve, Raises Price Target to $75

IPOs

PCLA

PicoCELA IPO Shares Open For Trade At $4/ADS; IPO Priced At $4/ADS

JPMorgan Chase &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) reported strong fourth-quarter results, along with <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43031980/big-banks-continue-to-beat-q4-earnings-financial-etf-takes-breather">solid results by other US big banks</a>.
The company reported its quarterly results amid an <a href="https://www.benzinga.com/earnings">exciting earnings season</a>. Here are some key analyst takeaways.
Goldman Sachs On JPMorgan Chase
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/595e3a7c988ca80001dc7d9c/richard-ramsden">Analyst Richard Ramsden</a> maintained a Buy rating, while lifting the price target from $273 to $295.
JPMorgan Chase reported fourth-quarter earnings of $4.81 per share, surpassing consensus of $4.08 per share, with core earnings also beating estimates, Ramsden said in a note. "The company also demonstrated strong expense discipline, with core expenses ~1% below the Street, despite stronger revenue," he added.
Management reiterated adjusted expenses for 2025 at around $95 billion, the analyst stated. "We view results and the 2025 NII (net interest income) and expense trajectory as better than expected," he further wrote.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Truist Securities On JPMorgan Chase
Analyst John McDonald reiterated a Hold rating and price target of $260.
JPMorgan Chase raised its 2025 NII ex-markets guidance to around $90 billion, "with lower short rates expected to produce sequential declines in 1H25 before flipping to sequential increases in 2H25 on loan/deposit growth," McDonald said.
The CFO indicated that JPMorgan Chase's overall deposit margin remains elevated, although "it&#8217;s still unclear if these current levels are truly sustainable through the cycle," the analyst stated. "Management noted they&#8217;re comfortable with this current level of excess capital and don&#8217;t believe it needs to grow any more," he further wrote.
JPM Price Action: Shares of JPMorgan Chase were up 0.4% to $253.26 at the time of publication on Thursday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43011444/wall-street-rallies-as-treasury-yields-fall-banks-smash-q4-earnings-oil-hits-80-whats-driving-markets-wednesday">Wall Street Rallies As Treasury Yields Fall, Banks Smash Q4 Earnings, Oil Hits $80: What&#8217;s Driving Markets Wednesday?</a></li>
</ul>
Photo: Konektus Photo/Shutterstock.com

Analyst Color

Earnings Beats

Reiteration

JPMorgan Exhibits 'Strong Expense Discipline' In Q4; Analysts See Backend-Loaded 2025

Plains All American's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAA#NYSE">PAA</a>) short percent of float has risen 32.89% since its last report. The company recently reported that it has 14.11 million shares sold short, which is 3.03% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.84 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Plains All American Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737047727_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Plains All American has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Plains All American's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Plains All American's peer group average for short interest as a percentage of float is 4.28%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(PAA) - Analyzing Plains All American's Short Interest

Main Street Capital's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAIN#NYSE">MAIN</a>) short percent of float has risen 17.94% since its last report. The company recently reported that it has 4.19 million shares sold short, which is 4.93% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.49 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Main Street Capital Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737047722_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Main Street Capital has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Main Street Capital's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Main Street Capital's peer group average for short interest as a percentage of float is 3.21%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

MAIN

Looking Into Main Street Capital's Recent Short Interest

Raymond James Finl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>) short percent of float has fallen 11.75% since its last report. The company recently reported that it has 5.19 million shares sold short, which is 3.23% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.43 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Raymond James Finl Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737047717_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Raymond James Finl has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Raymond James Finl's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Raymond James Finl's peer group average for short interest as a percentage of float is 3.19%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Raymond James Finl?

Barclays analyst Theresa Chen maintains Cheniere Energy Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CQP#NYSE">CQP</a>) with a Underweight and raises the price target from $46 to $54.

Barclays Maintains Underweight on Cheniere Energy Partners, Raises Price Target to $54

<a href="https://www.nytimes.com/2025/01/16/us/politics/trump-tiktok-executive-order.html" title="https://www.nytimes.com/2025/01/16/us/politics/trump-tiktok-executive-order.html">https://www.nytimes.com/2025/01/16/us/politics/trump-tiktok-executive-order.html</a>

ORCL

SNAP

'Trump Is Said To Consider Executive Order To Circumvent TikTok Ban; Order Would Allow TikTok To Continue Operating Until New Owners Are Found' - NYT

TD Cowen analyst Robert Moskow maintains Brown-Forman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) with a Hold and lowers the price target from $50 to $38.

BF/B

TD Cowen Maintains Hold on Brown-Forman, Lowers Price Target to $38

Barclays analyst Theresa Chen maintains Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>) with a Overweight and raises the price target from $202 to $253.

Barclays Maintains Overweight on Cheniere Energy, Raises Price Target to $253

Goldman Sachs analyst Mark Delaney maintains Cerence (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNC#NASDAQ">CRNC</a>) with a Neutral and raises the price target from $8 to $14.

CRNC

Goldman Sachs Maintains Neutral on Cerence, Raises Price Target to $14

The cryptocurrency market is experiencing a surge of optimism following signals of a <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43008666/sec-under-trump-administration-to-revise-crypto-policies-report">pro-crypto policy</a> shift from the incoming administration under President-elect Donald Trump.
<h2 class="wp-block-heading">Industry Cheers Pro-Crypto Pivot&#8230;</h2>
Key figures and investors in the crypto space have expressed relief at the anticipated policy change, buoyed by appointments of crypto-friendly individuals to prominent positions, including David Sacks as AI and crypto czar, and Paul Atkins as the nominee for SEC Chair.
These moves, coupled with expectations of executive orders designed to establish a Bitcoin reserve, <a href="https://nypost.com/2025/01/16/business/new-trump-ends-crypto-communitys-government-harassment/">according</a> to New York Post and halt debanking practices, signal a new era for the industry in the US.
Frank Chaparro, an early Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) investor, emphasized the magnitude of this shift, describing it as &#8220;a seismic change in the approach and tone of the government.&#8221;
He added that banks, which were previously discouraged from working with crypto firms, are expected to become active participants in the sector. 
Previously, many startups, facing regulatory hurdles and financial barriers, were forced to move their operations outside of the US. Now, this trend is expected to reverse with firms looking to move back, or expand into the US market. 
The overall mood within the crypto industry is one of optimism, as many anticipate a period of growth and innovation.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43032961/decentralized-finance-will-reshape-the-internet-crypto-founder-says">Decentralized Finance Will Reshape The Internet, Crypto Founder Says</a>
<h2 class="wp-block-heading">&#8230;But Not Everyone Agrees</h2>
However, with this enthusiasm comes debate regarding specific proposals, such as the nature of the proposed <a href="https://www.benzinga.com/25/01/43021074/oklahoma-joins-growing-list-of-states-proposing-bitcoin-as-strategic-reserve-asset">strategic reserve</a> and what kind of digital assets it would prioritize.
While there is a general consensus that the change in administration will improve the crypto space in the U.S., there are some varied views on how the implementation should work.
Many are anticipating the forthcoming executive orders and the details it will contain, as this will provide clarity on many of the questions being raised in the market. 
The market is also witnessing events such as the upcoming Crypto Ball in Washington D.C. which will be sponsored by key figures in the crypto space, which underscores the anticipation of a positive future for the crypto industry.
Alexander Grieve, VP of Government Affairs at Paradigm, <a href="https://x.com/AlexanderGrieve/status/1879871039108153404">cautioned</a> against taking press narratives at face value, urging stakeholders to wait for official communication directly from the President and his staff before making assumptions.
David Bailey, CEO at Bitcoin Magazine, also <a href="https://x.com/DavidFBailey/status/1879851786166771868">expressed</a> skepticism, particularly regarding proposals to favor U.S.-based digital assets. 
<h2 class="wp-block-heading">Strategic Bitcoin Reserve Interest On The Rise</h2>
Hunter Horsley, CEO of Bitwise, <a href="https://x.com/HHorsley/status/1879679937415954680">highlighted</a> the growing institutional interest in Bitcoin, saying that, "Nation-states are now asking about Bitcoin ETFs and considering shifting foreign reserves into BTC." 
Meanwhile, Senator Cynthia Lummis has <a href="https://x.com/Cointelegraph/status/1879914116648939746">raised</a> concerns about the U.S. Marshals Service&#8217;s plans to sell nearly 70,000 Bitcoin that were previously seized.
She has formally requested detailed information about this planned sale, citing potential losses and questioning the wisdom of liquidating such assets given the new administration&#8217;s pro-crypto stance. 
Her letter raises concerns about transparency, decision-making processes and long-term strategic planning regarding these Bitcoin holdings.
Read Next: 
<ul>
<li><a style="font-weight: bold;" href="https://www.benzinga.com/markets/cryptocurrency/25/01/43028215/coinbase-launches-bitcoin-backed-loans-for-us-users">Coinbase Launches Bitcoin-Backed Loans For US Users</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Donald Trump Reportedly Open To US Crypto Reserve As Bitcoin Reserve Chatter Gathers Steam

Goldman Sachs analyst Kash Rangan maintains BorgWarner (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWA#NYSE">BWA</a>) with a Neutral and lowers the price target from $35 to $31.

Goldman Sachs Maintains Neutral on BorgWarner, Lowers Price Target to $31

Diamond jewelry retailer Signet Jewelers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) is the subject of a new short report that comes as shares trade near 52-week lows after the company lowered <a href="https://www.benzinga.com/25/01/42975858/signet-jewelers-slashes-q4-sales-forecast-stock-drops-over-16">fourth-quarter guidance.</a>
Here's why The Bear Cave predicts more trouble ahead.
Signet's Increased Competition: The latest <a href="https://www.benzinga.com/topic/the-bear-cave">Bear Cave short report</a> targets the diamond jewelry company on the thesis that lab grown diamonds will continue to cut into Signet's market share.
"The Bear Cave believes today's youth and future generations will shift towards lab-grown diamond engagement rings and mined diamonds will be a vestige of the past," the <a href="https://thebearcave.substack.com/p/problems-at-signet-jewelers-sig">report </a>said.
Benzinga contacted Signet for comment on the report. 
Signet operates the Zales, Kay and Jared brands predominantly in malls with a key demographic being low-to-middle-income engagement ring shoppers, the report adds.
"The Bear Cave further believes the trend of lab-grown diamonds is accelerating quickly, will cause a strong devaluation in both mined and lab-grown diamond prices, and will cause Signet's business to suffer significantly."
A lower price point and ethics concerns over how diamonds are mined could result in the wave of young engagement ring buyers shifting to lab-grown diamonds, the report said.
The Bear Cave cites a rise of posts on social media talking about lab-grown diamonds and their positives as being a potential negative for Signet's future. The report highlights one user's post around the argument for buying an engagement ring that looks better at one-tenth the price and saving thousands of dollars that can be used to spend on a honeymoon or wedding.
Read Also: <a href="https://www.benzinga.com/trading-ideas/short-ideas/24/11/42152301/short-sellers-are-back-flurry-of-big-calls-from-muddy-waters-citron-and-others-raises-questions-why-now">Short Sellers Are Back – Flurry Of Big Calls From Muddy Waters, Citron And Others Raises Questions: Why Now?</a>
What's Next: The growth of lab-grown diamonds could threaten Signet's business model and send prices for diamonds even lower, the report said.
Signet has around $2 billion in inventory on its balance sheet, according to the report. This figure could decline over time and hurt the overall value of the company.
The rise of lab-grown diamonds could result in less frequent purchases of Signet&#8217;s extended service agreements, The Bear Cave said. Service agreements drive high-margin revenue for Signet and are frequently priced as a percentage of the cost of an engagement ring, the short report said, and will decline with the price of engagement rings. 
Signet recently lowered its fourth-quarter revenue guidance from a range of $2.38 billion to $2.46 billion to a new range of $2.32 billion to $2.335 billion. Shares fell in December after the company<a href="https://www.benzinga.com/news/earnings/24/12/42340973/signet-jewelers-stock-tanks-after-dismal-q3-print-guidance-cut"> reported third-quarter</a> revenue and earnings per share that missed analyst estimates. 
SIG Price Action: Signet stock is down 2.19% to $57.63 on Thursday versus a 52-week trading range of $54.44 to $112.06. Signet stock is down 21% over the last five days and down 31% over the last month.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/24/11/42119918/musk-ramaswamy-should-target-transdigm-in-budget-cuts-short-report-says-target-1-for-doge">Musk, Ramaswamy Should Target TransDigm In Budget Cuts, Short Report Says: &#8216;Target #1&#8217; For D.O.G.E.</a></li>
</ul>
Photo via Shutterstock.

Signet Jewelers Stock No Diamond In The Rough At 52-Week Lows, New Short Report Says 'Business To Suffer Significantly'

Goldman Sachs analyst Bruno Amorim maintains Azul (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZUL#NYSE">AZUL</a>) with a Neutral and lowers the price target from $3.1 to $2.7.

AZUL

Goldman Sachs Maintains Neutral on Azul, Lowers Price Target to $2.7

On Thursday, Outlook Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLK#NASDAQ">OTLK</a>) completed the analysis of the complete 12-week safety and efficacy results for NORSE EIGHT evaluating ONS-5010 in wet age-related macular <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g43023003/outlook-therapeutics-announces-complete-twelve-week-efficacy-and-safety-results-of-norse-eight-cli" rel="noreferrer noopener">degeneration (wet AMD) patients</a>.
ONS-5010 demonstrated non-inferiority to Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) / Roche Holdings AG&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) Lucentis (ranibizumab) at week 12 in the NORSE EIGHT trial. Based on the completed analysis of the 12-week results, Outlook Therapeutics plans to resubmit the Biologics License Application (BLA) for ONS-5010 in the first quarter of calendar 2025.
The difference in the mean between ONS-5010 and ranibizumab was -1.009 best corrected visual acuity (BCVA) letters.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37893076/why-is-eye-disease-focused-outlook-therapeutics-stock-trading-higher-on-friday" rel="noreferrer noopener">Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Higher On Friday?</a>
BCVA measures how well a person can see after wearing corrective lenses, such as glasses or contact lenses.
In the intent-to-treat (ITT) population, NORSE EIGHT demonstrated a mean 5.5 letter improvement in BCVA in the ONS-5010 arm and 6.5 letter improvement in BCVA in the ranibizumab arm.
As previously announced, in the NORSE EIGHT trial, ONS-5010 did not meet the pre-specified non-inferiority endpoint at week 8 outlined in the special protocol assessment (SPA) with the U.S. <a target="_blank" href="https://www.benzinga.com/24/11/42214804/why-is-eye-disease-focused-outlook-therapeutics-stock-trading-lower-on-wednesday" rel="noreferrer noopener">Food and Drug Administration (FDA)</a>.
However, BCVA data across all study timepoints demonstrated an improvement in vision, increasing over time, and the presence of biologic activity.
Overall, in NORSE EIGHT, ONS-5010 demonstrated mean visual acuity improvements of +3.3 letters at week 4, +4.2 letters at week 8, and +5.5 letters at week 12.
ONS-5010 was generally well-tolerated with overall ocular adverse event rates comparable to ranibizumab.
ONS-5010/LYTENAVA (bevacizumab gamma) has been approved in the European Union and the United Kingdom. Outlook Therapeutics intends to begin launching in Europe in the first half of calendar 2025.
The company also entered into agreements for warrant inducement transactions expected to result in up to $20.4 million in gross proceeds.
The company will use the proceeds to fund its ONS-5010 clinical development programs, the European commercial launch of LYTENAVA, and working capital and general corporate purposes.
Price Action: OTLK stock is down 9.78% at $2.06 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/01/43027745/ingevity-explores-strategic-options-for-performance-chemicals-segment-to-strengthen-portfolio-projects-fy24-revenue-at-1-40-billion" target="_blank" rel="noreferrer noopener">Ingevity Explores Strategic Options For Performance Chemicals Segment To Strengthen Portfolio, Projects FY24 Revenue At $1.40 Billion</a></li>
</ul>

Biotech

Financing

Offerings

OTLK

RHHBY

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

TD Cowen analyst Bill Katz upgrades Blue Owl Cap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>) from Hold to Buy and raises the price target from $26 to $28.

Upgrades

TD Cowen Upgrades Blue Owl Cap to Buy, Raises Price Target to $28

Raymond James analyst Patrick Tyler Brown maintains Vulcan Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMC#NYSE">VMC</a>) with a Outperform and lowers the price target from $298 to $295.

Raymond James Maintains Outperform on Vulcan Materials, Lowers Price Target to $295

The market kicked off with a notable rally, marking the return of what appears to be a "risk-on" environment.

Maximizing Gains: StoryTrading's Four Pillars Highlight The Best Plays Today

In a report released today, Suraj Kalia from Oppenheimer maintained a Buy rating on TransMedics Group (TMDX – Research Report), with a price target...

Oppenheimer Sticks to Its Buy Rating for TransMedics Group (TMDX)

TransMedics: A Cash Burn Problem That's Hard To Ignore

Scorpion Capital said in a newly-issued short report that in "20 years of shorting, TransMedics (TMDX) is the most extreme and grotesque healthcare...

TransMedics named as short idea with $0 target by Scorpion Capital

09:17 EST TransMedics (TMDX) down 10% to $65.39 after Scorpion Capital short report Published first on TheFly – the ultimate source for real-time, ...

TransMedics down 10% to $65.39 after Scorpion Capital short report

TransMedics Group drops after Scorpion Capital short call

TransMedics (TMDX) Group addressed what we believe are inaccurate and misleading claims made in a short-seller report issued by Scorpion Capital on...

TransMedics says claims made by Scorpion Capital 'have no merit'

Next Century Growth Investors Q4 2024 Commentary

Headwaters Capital Q4 2024 Investor Letter

TransMedics: Misplaced Fear

ADBE

ALHC

AMZN

APPF

ASTS

ATRO

AVAV

AVPT

AXON

BWIN

BYON

CAVA

CBLL

CDNA

CLMB

DXCM

FUBO

GDYN

GWRE

INOD

KIDS

KRUS

KTOS

LNTH

MNDY

MPTI

MPWR

MYRG

NSSC

NVDA

ODFL

PCTY

PEGA

PLTR

PNFP

PYCR

RXST

SAIA

SARO

SIBN

SPSC

TNDM

TOST

TSLA

USAP

VERX

VRRM

VRTX

WDAY

WEAV

WING

XMTR

Press Releases

TransMedics Responds to Inaccurate and Misleading Claims in Recent Short-Seller Report

Rosen Law Firm Encourages TransMedics Group, Inc. Investors to Inquire About Securities Class Action Investigation – TMDX

TransMedics Group (TMDX) Plunges Amidst Allegations of Fraud, Organ Trafficking – Hagens Berman

TMDX Investors Have Opportunity to Join TransMedics Group, Inc. Securities Fraud Investigation with the Schall Law Firm

TransMedics Group, Inc. Investors: Company Investigated by the Portnoy Law Firm

TransMedics Group (TMDX) Plunges Amidst Allegations of Fraud, Organ Trafficking - Hagens Berman

TMDX Investor News: Rosen Law Firm Encourages TransMedics Group, Inc. Investors to Inquire About Securities Class Action Investigation - TMDX

TransMedics Group, Inc. Announcement: If You Have Suffered Losses in TransMedics Group, Inc. (NASDAQ: TMDX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NASDAQ: TMDX Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages TransMedics Group, Inc. (NASDAQ: TMDX) Investors with Significant Losses to Contact the Firm

TRANSMEDICS ALERT: Bragar Eagel & Squire, P.C. is Investigating TransMedics Group, Inc. on Behalf of TransMedics Stockholders and Encourages Investors to Contact the Firm

Comments

TransMedics Gr

TransMedics Gr (TMDX) Options

TransMedics Gr (NASDAQ:TMDX) Stock, Option Chain

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga